| Anthony S. Fiorino |
Founder of EnzymeRx LLC, Anthony S. Fiorino is a businessperson who has been the head of 5 different companies and is Chairman, President, CEO & COO at Immune Pharmaceuticals, Inc.
In his past career he held the position of President & Chief Executive Officer at Triumvira Immunologics, Inc., Chief Executive Officer of Brainstorm Cell Therapeutics, Inc., President & Chief Executive Officer of EnzymeRx LLC, President for Alchimia Partners LLC, Managing Director at Greywall Asset Management LP, Portfolio Manager at Pequot Capital Management, Inc., Principal at Sands Point Partners LP and Principal at JPMorgan Services (Malaysia) Sdn. Bhd.
Anthony S. Fiorino received an undergraduate degree from Massachusetts Institute of Technology, a doctorate from Albert Einstein College of Medicine, Inc. and a doctorate from Albert Einstein College of Medicine, Inc. |
| Daniel Kazado |
Daniel Kazado is the founder of Dma Altiam. Mr. Kazado is on the board of Immune Pharmaceuticals, Inc. (former Chairman). |
| Elliot M. Maza |
Elliot M. Maza is a businessperson who has been at the head of 7 different companies. He occupies the position of Chairman, Chief Executive & Financial Officer at Intellect Neurosciences, Inc., President, CEO, CFO & Chief Accounting Officer at Immune Pharmaceuticals, Inc. and Chief Financial Officer of EnzymeRx LLC. He is also Member of New York State Bar Association.
In the past Mr. Maza held the position of Chairman at Auriga Laboratories, Inc., Chief Financial Officer of Truli Media Group, Inc., Director, Chief Executive & Financial Officer of Exactus, Inc., Chief Financial Officer of Emisphere Technologies, Inc., Chief Financial Officer of SolarWindow Technologies, Inc., Attorney at Sullivan & Cromwell LLP, Chief Executive Officer, CFO, Secretary & Director at BioZone Pharmaceuticals, Inc., President, CEO, CFO, Secretary & Treasurer at Camp Nine, Inc., Partner at Ernst & Young LLP, Vice President for Goldman Sachs, Inc., Vice President at Bankers Trust Securities and Vice President of JPMorgan Securities LLC.
Elliot M. Maza received an undergraduate degree from Touro College and a graduate degree from The University of Pennsylvania Law School. |
| John A. Neczesny |
John A. Neczesny is on the board of Immune Pharmaceuticals, Inc. In his past career he held the position of Managing Director at Oberon Securities LLC, Vice President-Corporate Development for Endo Generics Holdings, Inc. and Managing Director at Bear, Stearns & Co., Inc.
He received an undergraduate degree from the University of Delaware and an MBA from The Leonard N Stern School of Business. |
| Jeffrey Paley |
Founder of Crimson Biomedical Consulting and Access Medical Associates LLC, Jeffrey Paley currently holds the position of Chief Executive Officer of Crimson Biomedical Consulting. Dr. Paley is also on the board of Immune Pharmaceuticals, Inc., Avenue Therapeutics, Inc., Kalytera Therapeutics, Inc. and Caelum Biosciences, Inc.
In the past he occupied the position of Director-Clinical Research at Weill Cornell Internal Medicine Associates.
He received an undergraduate degree from Yeshiva University and a doctorate from Harvard Medical School. |
